CA3128321C - Dosage forms and therapeutic uses of l-4-chlorokynurenine - Google Patents

Dosage forms and therapeutic uses of l-4-chlorokynurenine Download PDF

Info

Publication number
CA3128321C
CA3128321C CA3128321A CA3128321A CA3128321C CA 3128321 C CA3128321 C CA 3128321C CA 3128321 A CA3128321 A CA 3128321A CA 3128321 A CA3128321 A CA 3128321A CA 3128321 C CA3128321 C CA 3128321C
Authority
CA
Canada
Prior art keywords
administration
chlorokynurenine
days
ameliorating
side effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3128321A
Other languages
English (en)
French (fr)
Other versions
CA3128321A1 (en
Inventor
H. Ralph Snodgrass
Allen E. Cato
Jack S. Hicklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vistagen Therapeutics Inc
Original Assignee
Vistagen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics Inc filed Critical Vistagen Therapeutics Inc
Priority to CA3216579A priority Critical patent/CA3216579A1/en
Publication of CA3128321A1 publication Critical patent/CA3128321A1/en
Application granted granted Critical
Publication of CA3128321C publication Critical patent/CA3128321C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)
CA3128321A 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine Active CA3128321C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3216579A CA3216579A1 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361849191P 2013-01-22 2013-01-22
US61/849,191 2013-01-22
CA2898619A CA2898619C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2898619A Division CA2898619C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3216579A Division CA3216579A1 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Publications (2)

Publication Number Publication Date
CA3128321A1 CA3128321A1 (en) 2014-07-31
CA3128321C true CA3128321C (en) 2023-12-05

Family

ID=51228003

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3128321A Active CA3128321C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine
CA2898619A Active CA2898619C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine
CA3216579A Pending CA3216579A1 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2898619A Active CA2898619C (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine
CA3216579A Pending CA3216579A1 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Country Status (22)

Country Link
US (8) US9993450B2 (enExample)
EP (4) EP4385563A3 (enExample)
JP (5) JP6436913B2 (enExample)
KR (5) KR102335919B1 (enExample)
CN (4) CN113116877A (enExample)
AU (5) AU2014209466B2 (enExample)
BR (1) BR112015017535A2 (enExample)
CA (3) CA3128321C (enExample)
CY (1) CY1122403T1 (enExample)
DK (3) DK2948140T3 (enExample)
ES (3) ES2980120T3 (enExample)
HK (1) HK1217170A1 (enExample)
HR (2) HRP20240812T1 (enExample)
HU (1) HUE067381T2 (enExample)
IL (3) IL291831A (enExample)
MX (2) MX375318B (enExample)
PL (2) PL3598971T3 (enExample)
PT (3) PT3598971T (enExample)
RS (1) RS59687B1 (enExample)
SI (2) SI3598971T1 (enExample)
WO (1) WO2014116739A1 (enExample)
ZA (2) ZA201505569B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59687B1 (sr) 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
IL296380A (en) * 2015-05-22 2022-11-01 Vistagen Therapeutics Inc Therapeutic uses of l-4-chlorokynurenine
HK1256902A1 (zh) * 2015-09-08 2019-10-04 Cephalon, Inc. 氯犬尿氨酸的前体药物
WO2019157426A1 (en) 2018-02-09 2019-08-15 Vistagen Therapeutics, Inc. Synthesis of 4-chlorokynurenines and intermediates
CN109223785A (zh) * 2018-10-29 2019-01-18 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用
WO2022082100A1 (en) * 2020-10-16 2022-04-21 Vistagen Therapeutics, Inc. Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5360814A (en) 1991-02-28 1994-11-01 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US7250394B2 (en) 2001-08-20 2007-07-31 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
JP2006502158A (ja) 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
MX2008013130A (es) 2006-04-12 2008-11-19 Probiodrug Ag Inhibidores de enzima.
EP1903028A1 (en) * 2006-09-22 2008-03-26 Werner Tschollar Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
US20110190347A1 (en) * 2008-08-21 2011-08-04 Richter Gedeon Nyrt. Methods for treating neuropathic pain
US8680042B2 (en) 2009-04-23 2014-03-25 Universität Zürich Prorektorat Mnw Methods of treating sickle cell anemia-related conditions with MK-801 or memantine
BRPI1014247A2 (pt) * 2009-06-17 2016-04-12 Targacept Inc reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais.
CN102667485B (zh) 2009-08-12 2015-04-22 福满代谢组技术有限公司 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP2338873A1 (en) * 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
JP6133772B2 (ja) * 2010-06-15 2017-05-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み治療用の医薬配合物
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
RS59687B1 (sr) 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
CN105164096A (zh) 2013-03-14 2015-12-16 维斯塔津治疗公司 手性犬尿氨酸化合物和中间体的合成
EP3062810A4 (en) 2013-10-28 2017-05-03 Naurex Inc. Nmda receptor modulators and prodrugs, salts, and uses thereof
IL296380A (en) 2015-05-22 2022-11-01 Vistagen Therapeutics Inc Therapeutic uses of l-4-chlorokynurenine

Also Published As

Publication number Publication date
ZA201505569B (en) 2017-01-25
ES2635353T3 (es) 2017-10-03
ES2751138T3 (es) 2020-03-30
DK3598971T3 (da) 2024-06-10
US20180369180A1 (en) 2018-12-27
US20160158178A1 (en) 2016-06-09
KR20210063449A (ko) 2021-06-01
ZA201607581B (en) 2019-04-24
US20250161251A1 (en) 2025-05-22
JP7021298B2 (ja) 2022-02-16
NZ710121A (en) 2021-01-29
IL276126B (en) 2022-05-01
AU2020204420A1 (en) 2020-07-23
RS59687B1 (sr) 2020-01-31
MX2015009277A (es) 2015-12-11
EP4385563A2 (en) 2024-06-19
AU2018253600A1 (en) 2018-11-22
AU2018253600B2 (en) 2020-07-09
EP3228313B1 (en) 2019-09-11
US10980758B2 (en) 2021-04-20
AU2014209466A1 (en) 2015-08-06
US20190133984A1 (en) 2019-05-09
JP2020183400A (ja) 2020-11-12
DK3228313T3 (da) 2019-11-25
HK1217170A1 (zh) 2016-12-30
CA2898619A1 (en) 2014-07-31
AU2024278564A1 (en) 2025-01-09
KR20230003410A (ko) 2023-01-05
SI3228313T1 (sl) 2019-12-31
US12036198B2 (en) 2024-07-16
US20150359772A1 (en) 2015-12-17
CY1122403T1 (el) 2021-01-27
CA3128321A1 (en) 2014-07-31
US9993450B2 (en) 2018-06-12
DK2948140T3 (en) 2017-08-21
HUE067381T2 (hu) 2024-10-28
US20190125707A1 (en) 2019-05-02
IL276126A (en) 2020-08-31
US9993453B2 (en) 2018-06-12
CA3216579A1 (en) 2014-07-31
CA2898619C (en) 2021-10-19
PT2948140T (pt) 2017-08-10
HRP20192189T1 (hr) 2020-02-21
JP2016505050A (ja) 2016-02-18
AU2022221382B2 (en) 2024-09-19
ES2980120T3 (es) 2024-09-30
JP2019023195A (ja) 2019-02-14
PL3228313T3 (pl) 2020-03-31
US20220409564A1 (en) 2022-12-29
JP6804497B2 (ja) 2020-12-23
EP2948140A1 (en) 2015-12-02
SI3598971T1 (sl) 2024-10-30
KR102335919B1 (ko) 2021-12-07
IL240090B (en) 2020-08-31
US10632091B2 (en) 2020-04-28
IL291831A (en) 2022-06-01
CN113116877A (zh) 2021-07-16
EP4385563A3 (en) 2024-08-21
AU2014209466B2 (en) 2018-11-08
AU2022221382A1 (en) 2022-09-15
HRP20240812T1 (hr) 2024-09-27
PT3228313T (pt) 2019-12-17
WO2014116739A1 (en) 2014-07-31
CN105073108A (zh) 2015-11-18
US20180289649A1 (en) 2018-10-11
EP2948140B1 (en) 2017-05-10
MX375318B (es) 2025-03-06
EP3598971B1 (en) 2024-03-20
CN113209068A (zh) 2021-08-06
US10617663B2 (en) 2020-04-14
KR20210149905A (ko) 2021-12-09
EP2948140A4 (en) 2016-08-03
JP2022070894A (ja) 2022-05-13
PL3598971T3 (pl) 2024-09-09
KR20230098711A (ko) 2023-07-04
KR20150109428A (ko) 2015-10-01
KR102257284B1 (ko) 2021-05-28
IL240090A0 (en) 2015-09-24
CN112933073A (zh) 2021-06-11
PT3598971T (pt) 2024-06-20
JP6436913B2 (ja) 2018-12-12
EP3598971A1 (en) 2020-01-29
MX2020009966A (es) 2020-10-12
JP2024069257A (ja) 2024-05-21
EP3228313A1 (en) 2017-10-11
BR112015017535A2 (pt) 2020-02-04

Similar Documents

Publication Publication Date Title
AU2022221382B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK40022228A (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
HK40022228B (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
HK40059702A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK40056816A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK40054519A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
NZ710121B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211116

EEER Examination request

Effective date: 20211116

EEER Examination request

Effective date: 20211116

EEER Examination request

Effective date: 20211116

EEER Examination request

Effective date: 20211116

EEER Examination request

Effective date: 20211116

EEER Examination request

Effective date: 20211116

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117